TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pasithea Therapeutics Corp ( (KTTA) ) has shared an update.
On November 28, 2025, Pasithea Therapeutics Corp announced a public offering of 80,000,000 shares of common stock or pre-funded warrants, raising approximately $60 million in gross proceeds. The offering, which closed on December 1, 2025, was led by healthcare-focused investors and is expected to extend the company’s cash runway through at least the first half of 2028. The net proceeds will be used for general corporate purposes, including ongoing research, clinical trials, and potential acquisitions. Company insiders, including executives and board members, participated in the offering, purchasing shares at the same price as other investors.
More about Pasithea Therapeutics Corp
Pasithea Therapeutics Corp is a clinical-stage biotechnology company focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor. This drug is intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The company is currently conducting Phase 1 clinical trials for PAS-004 in advanced cancer patients and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas.
Average Trading Volume: 6,759,192
Technical Sentiment Signal: Hold
Current Market Cap: $8.63M
For detailed information about KTTA stock, go to TipRanks’ Stock Analysis page.